NERV Insider Trading
Insider Ownership Percentage: 10.40%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
Minerva Neurosciences Share Price & Price History
Current Price: $6.25
Price Change: ▼ Price Decrease of -0.07 (-1.11%)
As of 02/24/2026 05:00 PM ET
Minerva Neurosciences Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/1/2023 | Frederick W Ahlholm | CFO | Sell | 3,580 | $4.48 | $16,038.40 | 17,518 | |
| 5/1/2023 | Geoff Race | President | Sell | 22,082 | $3.85 | $85,015.70 | 51,324 | |
| 5/1/2023 | Remy Luthringer | CEO | Sell | 23,753 | $3.85 | $91,449.05 | 72,635 | |
Minerva Neurosciences Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 2/18/2026 | Millennium Management LLC | 137,911 | $0.55M | 0.0% | N/A | 0.319% |  |
| 2/18/2026 | Janus Henderson Group PLC | 9,000 | $36K | 0.0% | N/A | 0.021% |  |
| 2/17/2026 | Logos Global Management LP | 3,311,000 | $13.31M | 0.8% | N/A | 7.652% |  |
| 2/17/2026 | Ally Bridge Group NY LLC | 1,655,500 | $6.66M | 6.9% | N/A | 3.826% |  |
| 2/17/2026 | Farallon Capital Management LLC | 2,365,000 | $9.51M | 0.0% | N/A | 5.466% |  |
| 2/17/2026 | Adage Capital Partners GP L.L.C. | 2,838,000 | $11.41M | 0.0% | N/A | 6.559% |  |
| 2/16/2026 | Spruce Street Capital LP | 1,655,500 | $6.66M | 2.2% | N/A | 3.826% |  |
| 2/13/2026 | Vivo Capital LLC | 4,322,747 | $17.38M | 1.1% | N/A | 9.990% |  |
| 2/13/2026 | State Street Corp | 24,019 | $97K | 0.0% | +45.4% | 0.056% |  |
| 2/12/2026 | Renaissance Technologies LLC | 149,200 | $0.60M | 0.0% | +28.1% | 0.345% |  |
| 2/12/2026 | Federated Hermes Inc. | 5,371,775 | $21.60M | 0.0% | +297.5% | 12.415% |  |
| 2/9/2026 | Geode Capital Management LLC | 69,919 | $0.28M | 0.0% | -7.5% | 0.162% |  |
| 1/21/2026 | Apella Capital LLC | 42,380 | $0.17M | 0.0% | +7.8% | 0.098% |  |
| 10/17/2025 | Apella Capital LLC | 39,314 | $83K | 0.0% | +87.8% | 0.000% |  |
| 4/10/2025 | Apella Capital LLC | 20,625 | $35K | 0.0% | N/A | 0.295% |  |
| 2/17/2025 | Citadel Advisors LLC | 25,764 | $57K | 0.0% | +49.5% | 0.369% |  |
| 2/14/2025 | Northern Trust Corp | 36,878 | $82K | 0.0% | +60.0% | 0.528% |  |
| 2/13/2025 | Renaissance Technologies LLC | 128,100 | $0.29M | 0.0% | -18.5% | 1.833% |  |
| 8/9/2024 | Renaissance Technologies LLC | 167,700 | $0.54M | 0.0% | -5.7% | 2.398% |  |
| 11/13/2023 | Acadian Asset Management LLC | 17,423 | $0.12M | 0.0% | -18.8% | 0.249% |  |
| 8/7/2023 | Acadian Asset Management LLC | 21,463 | $0.20M | 0.0% | -24.3% | 0.307% |  |
| 7/27/2023 | Virtu Financial LLC | 20,993 | $0.19M | 0.0% | N/A | 0.377% |  |
| 11/14/2022 | Point72 Asset Management L.P. | 25,000 | $0.23M | 0.0% | N/A | 0.468% |  |
| 10/26/2022 | Truist Financial Corp | 11,043 | $0.10M | 0.0% | N/A | 0.207% |  |
| 9/16/2022 | Federated Hermes Inc. | 1,201,275 | $3.98M | 0.0% | -87.5% | 22.496% |  |
| 2/10/2022 | Acadian Asset Management LLC | 1,768,685 | $1.41M | 0.0% | +3.4% | 4.140% |  |
| 11/16/2021 | Two Sigma Securities LLC | 16,788 | $29K | 0.0% | N/A | 0.039% |  |
| 11/15/2021 | Dimensional Fund Advisors LP | 740,056 | $1.29M | 0.0% | -30.7% | 1.732% |  |
| 11/12/2021 | Renaissance Technologies LLC | 754,116 | $1.31M | 0.0% | -24.7% | 1.765% |  |
| 11/9/2021 | BlackRock Inc. | 488,370 | $0.85M | 0.0% | +20.2% | 1.143% |  |
Data available starting January 2016
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Read More on Minerva Neurosciences
Volume
113,896 shs
Average Volume
109,584 shs
Market Capitalization
$270.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
Who are the major institutional investors of Minerva Neurosciences?
Which major investors are selling Minerva Neurosciences stock?
Within the previous quarter, NERV stock was sold by these institutional investors:
- Geode Capital Management LLC
Which major investors are buying Minerva Neurosciences stock?
Within the previous quarter, NERV stock was purchased by institutional investors including:
- Vivo Capital LLC
- Federated Hermes Inc.
- Logos Global Management LP
- Adage Capital Partners GP L.L.C.
- Farallon Capital Management LLC
- Ally Bridge Group NY LLC
- Spruce Street Capital LP
- Millennium Management LLC